Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 7/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27245877 | 0.84 | RYR2 (0.44) | RYR2ABHD6 | |
| SCHEMBL29972597 | 0.84 | RYR2 (0.44) | RYR2ABHD6 | |
| SCHEMBL30850927 | 0.81 | RYR2 (0.37) | RYR2ABHD6KMT2A | |
| SCHEMBL24761127 | 0.80 | ABHD6 (0.45) | RYR2ABHD6MAPT | |
| SCHEMBL29972813 | 0.80 | ABHD6 (0.45) | RYR2ABHD6MAPT | |
| SCHEMBL31463192 | 0.79 | RYR2 (0.57) | RYR2ABHD6HPGDS1PR1 | |
| SCHEMBL31021192 | 0.75 | HPGD (0.40) | RYR2KMT2AHPGDSMN1; SMN2MAPT | |
| SCHEMBL27245848 | 0.75 | MAPT (0.40) | RYR2ABHD6KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL24760956 | 0.75 | HPGD (0.40) | RYR2KMT2AHPGDSMN1; SMN2MAPT | |
| SCHEMBL25424219 | 0.74 | RYR2 (0.44) | RYR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| US-20240116909-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240116909-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116909-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, CGAS, IRF3 | RYR2 2290/4885ABHD6 2937/4885KMT2A 4725/4885 |
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | RYR2 1921/4885ABHD6 4080/4885KMT2A 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.